parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.01 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including microglia; strongest in mast cells	0.75
chemistry Open Targets	hard to drug	0.27
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	1 Parkinson's papers of 31	0.91
pathways Reactome	8 pathways; mostly growth signalling	0.60

No case: the score is under the bar. Receipt 12136

PIK3R6 in dopamine neurons, braak-0.29 (p 0.445) → -0.41 (p 0.272)receipt 12143
PIK3R6 in microglia, braak-0.08 (p 0.840) → -0.15 (p 0.702)receipt 12142

receipt 12143: PIK3R6 in dopamine neurons, braak

power: full sample -0.26 (p 0.289, n 18), 95% CI -0.65 to +0.23. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.30 (p 0.225, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.38 (p 0.118, n 18). could be the mix.
skeptic: leave-one-out range -0.42 to -0.18, sign flips 0; without severely affected donors -0.26 (p 0.289, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for PIK3R6 in dopamine neurons.

case closed: nothing better to follow up.

receipt 12142: PIK3R6 in microglia, braak

power: full sample -0.22 (p 0.384, n 18), 95% CI -0.62 to +0.28. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.27 (p 0.281, n 18). does not hold up.
composition: microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: -0.25 (p 0.310, n 18). could be the mix.
skeptic: leave-one-out range -0.37 to -0.11, sign flips 0; without severely affected donors -0.22 (p 0.384, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for PIK3R6 in microglia.

case closed: nothing better to follow up.

loading the receipts